香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願性公告 TY-302、TY-2699a及TY-0540的I期臨床試驗結果獲2025年 歐洲腫瘤內科學會(ESMO)大會以壁報形式收錄 浙江同源康醫藥股份有限公司（「本公司」），連同其附屬公司統稱（「本集團」）自願 刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 本公司董事會（「董事會」）欣然宣佈，公司自主研發的三款臨床產品TY-302、 TY-2699a及TY-0540的I期臨床試驗結果，正式獲2025年歐洲腫瘤內科學會 (ESMO)大會以壁報形式收錄。相關詳細數據將於會議期間展示，並同步發表於 ESMO官方期刊《Annals of Oncology》。 關於CDK4/6抑制劑TY-302 TY-302是一種為治療乳腺癌及前列腺癌等晚期實體瘤而開發的強 ...

Group 1 - The HR+/HER2- breast cancer subtype accounts for approximately 70% of all breast cancer cases globally, with over 2.2 million new cases annually, including about 1.5 million HR+/HER2- cases [1] - Current first-line treatment involves CDK4/6 inhibitors combined with endocrine therapy, but nearly all patients eventually develop resistance, with a median resistance duration of 12-18 months [1] - There are currently no approved targeted therapies for patients who have developed resistance to CDK4/6 inhibitors, and existing second-line options show limited efficacy, with an objective response rate of only 5-10% and median progression-free survival of 3-6 months [1] Group 2 - TY-00540 is a globally leading dual-target CDK2/4 inhibitor that addresses the key mechanism of resistance to CDK4/6 inhibitors by upregulating CDK2 activity [2] - Preclinical studies indicate that TY-00540 demonstrates nanomolar-level inhibitory activity against both CDK2/cyclin E and CDK4/cyclin D1, significantly outperforming single-target CDK4/6 inhibitors or chemotherapy [2] - By simultaneously inhibiting CDK4/6 and CDK2, TY-00540 effectively blocks tumor cell cycle progression, overcoming resistance to CDK4/6 inhibitors [2] Group 3 - The ESMO 2025 conference will present specific data from the Phase I clinical trial of TY-00540, led by Professor Zhang Jian from Fudan University Shanghai Cancer Center [3] - Preliminary results suggest that TY-00540 shows significant anti-tumor activity and manageable safety in patients who have developed resistance to first-line CDK4/6 inhibitors, with objective response rates and disease control rates superior to existing second-line options [3] - The overall safety profile of TY-00540 is favorable, with most treatment-related adverse events being mild to moderate [3]

Core Viewpoint - The announcement by Tongyuan Kang Pharmaceutical regarding the inclusion of three innovative drugs in the upcoming ESMO conference highlights the early clinical value recognized by the international academic community [1] Group 1: Drug Highlights - The CDK2/4 inhibitor TY-00540 shows broad anti-tumor potential, demonstrating strong inhibitory effects on key targets such as CDK2/CycA2 and CDK4/CycD1, with significant efficacy in breast and ovarian cancers [2] - The CDK7 inhibitor TY-2699a exhibits high selectivity for CDK7, with preclinical studies confirming its ability to inhibit cancer cell growth at non-toxic doses to normal cells, showing promising safety and efficacy in early clinical data [3] - The differentiated CDK4/6 inhibitor TY-302 presents a better treatment experience with lower gastrointestinal side effects and manageable hematological toxicity, demonstrating significant efficacy and safety in combination therapy for HR+/HER2- advanced breast cancer [4]

Core Viewpoint - The core product TY-9591 from Sameorigin Pharma made its debut at the ASCO annual meeting, gaining significant attention due to its promising clinical results against the leading lung cancer drug, Osimertinib [1] Group 1: Product Overview - TY-9591 is an oral, irreversible third-generation EGFR inhibitor specifically targeting non-small cell lung cancer (NSCLC) with brain metastases, aiming to challenge Osimertinib's market dominance [2] - It is the first and only drug to show significant improvement over Osimertinib in head-to-head clinical studies for this indication [2] - The drug's pharmacokinetic properties have been optimized by substituting hydrogen atoms in Osimertinib's molecule with deuterium, resulting in a threefold increase in brain tissue concentration compared to Osimertinib [2] Group 2: Clinical Trial Results - In a key Phase II clinical trial, TY-9591 achieved the primary endpoint of intracranial objective response rate (iORR), demonstrating statistically significant and clinically meaningful improvements over Osimertinib across various patient subgroups [3] - The drug is positioned as the fastest-developing candidate for treating NSCLC with brain metastases, potentially reshaping the treatment landscape in China [3] Group 3: Market Potential - The EGFR-TKI market in China has shown significant growth, increasing from 3.1 billion yuan in 2017 to 14.5 billion yuan in 2023, with a compound annual growth rate of 29.3% [4] - The market for third-generation EGFR-TKIs is expected to exceed 20.1 billion yuan by 2027 and 28.4 billion yuan by 2033 [4] - There is a pressing need for innovative treatments for NSCLC with brain metastases, as current standard therapies have limited efficacy, with objective response rates of only 23%-45% [5][6] Group 4: Commercialization Outlook - TY-9591 is set to submit its NDA for conditional approval in China, with the potential to capture significant market share given Osimertinib's current sales exceeding 8 billion yuan [6] - The successful commercialization of TY-9591 is crucial for Sameorigin Pharma's path to profitability [6]

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 董事名單與其角色和職能 浙江同源康醫藥股份有限公司董事會（「董事會」）成員如下。 執行董事 | | 委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 科學委員會 | | 吳豫生博士 | | | M | C | C | | 李鈞博士 | | M | | | M | | 顧虹博士 | | | | | | | 蔣鳴昱博士 | | | | | | | 孟曉英博士 | | | | | | | 何超先生 | | | | | | | 朱向陽博士 | | | | | | | 張森泉先生 | | C | M | M | | | 冷瑜婷博士 | | M | C | M | | | 許文青博士 | | | | | M | | 沈秀華博士 | | | | | | 附註： 吳豫生博士 非執行董事 李鈞博士 顧虹博士 蔣鳴昱博士 孟曉英博士 何超先生 朱向陽博士 獨立非執行董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 於2025年6月26日舉行的2024年年度股東大會投票表決結果； 及委任非執行董事 浙江同源康醫藥股份有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司於 2025年6月26日（星期四）下午一時正於中國上海市徐匯區龍蘭路277號東航濱江 中心T2幢8樓召開的2024年年度股東大會（「年度股東大會」）的投票表決結果。茲 提述本公司日期為2025年5月29日的年度股東大會通告及通函（「通函」）。除另有 所指，本公告所用詞彙與通函所界定者具相同涵義。 2024年年度股東大會投票表決結果 年度股東大會由董事會召開並由董事長吳豫生博士主持。全體董事，即吳豫生博 士、李鈞博士、顧虹博士、蔣鳴昱博士、孟曉英博士、何超先生、張森泉先生、 冷瑜婷博士、許文青博士及沈秀華博士均親身或通過 ...

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing a revaluation opportunity after a prolonged downturn, with significant increases in the biotech sector, particularly for companies like Sihuan Pharmaceutical [1][2] Group 1: Company Overview - Sihuan Pharmaceutical's core product, TY-9591, has shown significant clinical improvements in treating non-small cell lung cancer (NSCLC) compared to the leading drug, Osimertinib [2][4] - The company submitted a Pre-NDA application in April and is expected to submit a conditional NDA application in Q2 of this year, marking a critical milestone for the commercialization of TY-9591 [5][7] Group 2: Market Potential - The NSCLC market in China is substantial, with approximately 85% of lung cancer cases being non-small cell, and EGFR mutations being the most common genetic alterations [5][6] - The market for EGFR-TKI drugs is projected to exceed 20.44 billion yuan in 2024, with a year-on-year growth of 19.5%, indicating a robust demand for innovative treatments [6] Group 3: Competitive Landscape - TY-9591 has demonstrated superior efficacy and safety compared to Osimertinib, particularly in patients with brain metastases, positioning it as a potential game-changer in the lung cancer treatment market [4][6] - The market currently dominated by Osimertinib, which is expected to generate over 8 billion yuan in sales in China in 2024, presents a significant opportunity for Sihuan Pharmaceutical to capture market share with TY-9591 [6][7] Group 4: Investment Sentiment - Recent market activity indicates increasing investor interest in Sihuan Pharmaceutical, with significant net inflows and a rising shareholding among Hong Kong Stock Connect investors [7] - The company's current market capitalization of approximately 6 billion yuan suggests considerable upside potential compared to peers that have seen substantial stock price increases following positive clinical trial results [7]

吳豫生博士 非執行董事 李鈞博士 顧虹博士 蔣鳴昱博士 孟曉英博士 何超先生 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 董事名單與其角色和職能 浙江同源康醫藥股份有限公司董事會（「董事會」）成員如下。 執行董事 獨立非執行董事 張森泉先生 冷瑜婷博士 許文青博士 沈秀華博士 附註： C 有關董事會委員會主席 M 有關董事會委員會成員 香港，2025年6月13日 2 1 董事會設立四個委員會。下表提供各董事會成員所在委員會的成員資料。 | | 委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 科學委員會 | | 吳豫生博士 | | | M | C | C | | 李鈞博士 | | M | | | M | | 顧虹博士 | | | | | | | 蔣鳴昱博士 | | | | | | | 孟曉英博士 | | | | | | | 何超先生 | | | | | | | 張森泉先生 | | C | M | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 內幕消息 本公司申請H股全流通 本公告乃由浙江同源康醫藥股份有限公司（「本公司」）根據香港聯合交易所有限公 司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條 例第XIVA部項下內幕消息條文作出。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2025年6月6日，本公司已就將 本公司4,608,000股非上市股股份（「非上市股份」）轉換為H股（「H股」）以及該等股 份於聯交所上市（「H股全流通」）向中國證監會提交申請（「該申請」）。在取得所有 相關監管機構（包括但不限於中國證監會及聯交所）的備案及╱或批准及符合所有 適用法律、法規及規則後，該等非上市股份將被轉換為H股及合資格在聯交所主 板上市買賣，有關詳情如下： 1 佔本公司 將轉 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 10. 考慮及批准購回H股的購回授權。 11. 考慮及批准公司章程修正案。 承董事會命 （股份代號：2410） 2024年年度股東大會通告 茲通告浙江同源康醫藥股份有限公司（「本公司」）謹訂於2025年6月26日（星期 四）下午一時正於中國上海市徐匯區龍蘭路277號東航濱江中心T2幢8樓舉行2024年年 度股東大會（「年度股東大會」），藉以審議及酌情通過下列決議案。除另有所指，本通 告所用詞彙與本公司日期為2025年5月29日之通函所界定者具相同涵義。 普通決議案 – 1 – 1. 考慮及批准2024年度董事會報告。 2. 考慮及批准2024年度監事會報告。 3. 考慮及批准2024年年度報告。 4. 考慮及批准2024年經審核財務報表。 5. 考慮及批准2025年度董事及監事酬金。 6. 考慮 ...